




ATC codes: **A07EC01**

Indication	Crohn disease site <span style="background-color: #008080; color: white; padding: 2px;">ICD11 code: DD70.Z</span>
INN	Sulfasalazine
Medicine type	Chemical agent
List type	Core
Formulations	Oral > Solid: 500 mg Local > Rectal > Suppository: 500 mg Local > Rectal > Retention enema:
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1979 ( <a href="#">TRS 641</a> ) Changed in 1987 ( <a href="#">TRS 770</a> ) Changed in 1993 ( <a href="#">TRS 850</a> ) Changed in 1997 ( <a href="#">TRS 882</a> ) Changed in 2003 ( <a href="#">TRS 920</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	mesalazine (ATC codes: A07EC02)
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Sulfasalazine</a> 
DrugBank	<a href="#">Sulfasalazine</a> 

### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended mesalazine be specified as a therapeutic alternative under the square box listing for sulfasalazine on the EML for this indication.

